Most people have never heard of lipoprotein(a) — yet it is a potentially lifesaving cardiovascular marker that current guidelines recommend everyone get tested for at least once. Unlike LDL cholesterol or blood pressure, Lp(a) is almost entirely genetic: no diet, no exercise programme, and no supplement will meaningfully shift it. That means the only way to know whether it is a personal risk factor is to test for it. And the results can fundamentally change how aggressively someone needs to manage their overall heart disease risk.
The test costs as little as $51 in the United States and typically needs to be done only once in a lifetime. Yet fewer than 2% of people have ever had it done — despite roughly 1 in 5 having elevated levels [6]. This guide covers what Lp(a) is, what the latest evidence says about its risk, and what to do if levels come back high.
Table of Contents
- What is Lp(a) and why does it matter?
- The numbers that reveal the danger
- What to do if your levels are high
- Future treatments on the horizon
- Final thoughts
- References
What is Lp(a) and why does it matter?
The evidence connecting Lp(a) to heart attacks and strokes has been steadily building in recent years. A large study published in the European Heart Journal provides some of the most sobering numbers to date.
The study drew on a large database to identify almost 300,000 people with diagnosed heart disease. Researchers examined follow-up data for about five years to see who had a heart attack or stroke, and how those numbers relate to Lp(a) [1].
Compared to those with Lp(a) levels less than 15 nmol/L, those with levels between 15 and 79 had a 4% greater risk. With levels between 80–179, it was 15% greater. The risk jumped to 29% higher for levels from 180 to 299, and a sobering 45% greater risk above 300 [1].
What's more, the research shows risk increases continuously the higher Lp(a) levels go, starting from the lowest levels. Past 300 nmol/L, the risk just keeps rising [1].
This risk applies not only to people already diagnosed with heart disease. The lifetime risk of a heart attack or stroke for the general population follows the same dose–response pattern. Based on data from the UK Biobank, higher Lp(a) levels translate into substantially higher lifetime risks [2].
Knowing an individual's Lp(a) level is crucial for getting an accurate picture of their overall cardiovascular risk.
A common misconception is that a healthy weight, clean diet, non-smoking status, and normal blood pressure mean Lp(a) is probably fine. That assumption can be dangerous. Unlike most other cardiovascular risk factors, Lp(a) levels are almost exclusively driven by genetics — not by lifestyle factors [2].
This means the only way to know one's levels is through testing. But first, it helps to understand what lipoprotein(a) actually is and how scientists think it contributes to cardiovascular disease.
Most people are familiar with lipoproteins as the "L" in HDL and LDL when discussing cholesterol. Lipoproteins are transport vehicles for cholesterol and triglycerides in the bloodstream. Cholesterol and water do not mix naturally — think of how oil separates from water. Blood is mostly water, so the body needs lipoproteins to carry cholesterol through the circulation.
While LDL particles are far more numerous, Lipoprotein(a) appears to be particularly inflammatory and causes approximately 6 times as much vascular damage compared to a regular LDL particle [3].
The numbers that reveal the danger
Checking Lp(a) levels requires only a simple blood test — as straightforward as checking HDL and LDL cholesterol levels. Cost and availability vary by country. In the United States, the test is available for $51 through Quest Diagnostics [4].
In New Zealand, the test can be obtained for even less [5].
One of the practical advantages of this test is that it only needs to be done once. Because Lp(a) is genetically determined, levels remain stable throughout life unless certain acute health conditions are present.
What counts as a high level? A commonly used threshold is above 50 mg/dL (or 105 nmol/L), while a level between 30–50 mg/dL (62–105 nmol/L) is considered elevated [6].
The stakes are significant. The 5% of the population with the highest Lp(a) concentrations face 3 times the risk for a heart attack and a narrowing of the aortic valve. They have 1.6 times the risk for a stroke and 1.5 times the risk of death from cardiovascular disease [6].
Population data shows that approximately 1 in 5 people have elevated Lp(a) levels — yet only 1–2% of the population ever gets tested [6]. This means millions of people are walking around with a significant, modifiable-risk-relevant factor they have never been assessed for.
What to do if your levels are high
If Lp(a) comes back elevated, what does current evidence and guideline guidance recommend?
With elevated LDL cholesterol, the standard approach is to target lifestyle changes first, then add medication to drive levels down further if necessary. Lp(a) is different. Because levels are primarily driven by genetics, there are no lifestyle interventions that will significantly shift the numbers. No medication is yet specifically approved for lowering Lp(a) [2].
Current guidelines therefore recommend a different strategy: focus on bringing every other modifiable cardiovascular risk factor under as tight control as possible. All risk factors compound — total cardiovascular risk is a function of both Lp(a) burden and contributions from other factors [2].
The key modifiable factors are well known: LDL cholesterol level, blood pressure, blood sugar control, and BMI. Lifestyle modifications covering diet and regular exercise can meaningfully move all of these.
For individuals with elevated Lp(a), clinical guidelines support an aggressive LDL-c target of 40–50 mg/dL. LDL acts as fuel for plaque build-up in the arteries, and reducing LDL starves that process. Reaching this target typically requires a combination of lifestyle changes, a low-dose statin, and ezetimibe — both of which are inexpensive and have well-established safety profiles. Although statins can slightly increase Lp(a) levels, they dramatically reduce LDL-c, and the net effect is a lower overall cardiovascular risk.
A subgroup analysis from the large cohort study described above looked specifically at hazard ratios for individuals who aggressively lowered their LDL-c compared to those who did not. The findings were striking: the cardiovascular risk for those in the highest Lp(a) category ended up being essentially the same as for those in the lowest Lp(a) category who were not on LDL-c-lowering therapy [1].
The confidence intervals in that subgroup analysis are wide, and further studies are needed to confirm this effect. But this evidence strongly supports pursuing aggressive LDL-c reduction in anyone with elevated Lp(a).
Future treatments on the horizon
There is one existing class of medication that can directly lower Lp(a) levels, though not yet FDA-approved specifically for this indication: PCSK9 inhibitors. Designed primarily to lower LDL-c, they also reduce Lp(a) by 15–30% [2]. The main barrier is cost — PCSK9 inhibitors remain expensive compared to statins and ezetimibe.
Aspirin may also be considered in patients whose Lp(a) levels combined with other risk factors create a high overall risk profile, though its use requires individual clinical assessment.
More promising therapies are in development. In early clinical trials, olpasiran — an RNA-interference therapeutic targeting Lp(a) synthesis — produced an average decrease in Lp(a) levels of 97%, sustained over 6 months, with a good safety profile to date [2].
The critical next step for olpasiran and similar agents is demonstrating that this Lp(a) reduction translates into fewer cardiovascular events — heart attacks and cardiovascular deaths — in a placebo-controlled outcome trial. That trial for olpasiran is currently underway, with projected completion in the coming years [7].
Final thoughts
Lipoprotein(a) is a genetic cardiovascular risk factor that approximately 1 in 5 people have in elevated range — and most are unaware. A one-time blood test, available for around $51 in the US, provides a lifelong data point that can change how aggressively someone manages their heart health.
For now, the evidence-based strategy for elevated Lp(a) centres on aggressive LDL-c reduction through lifestyle modifications combined with statin and ezetimibe therapy when needed. Discovering elevated Lp(a) is not a cause for alarm — but it is a clear signal that cardiovascular risk factors need to be managed with greater precision and urgency.
With promising Lp(a)-specific therapies like olpasiran advancing through clinical trials, the outlook for people with high Lp(a) is improving. Getting tested is the first — and most important — step.
References
1. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf297/8124887
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9639807/
3. https://pubmed.ncbi.nlm.nih.gov/38233012/
4. https://www.questhealth.com/product/lipoprotein-a-lpa-test-34604M.html
5. https://www.mytests.co.nz/our-tests/lipoprotein-a/
6. https://www.sciencedirect.com/science/article/pii/S0021915025001169
